Nightingale Health Plc
Company release, inside information
28 June 2024 at 9:35 a.m. (EEST)

Nightingale Health Plc’s US subsidiary Nightingale Health United States, Inc. (“Nightingale Health”) and Boston Heart Diagnostics Corporation (“Boston Heart”) have signed a service agreement to provide Nightingale’s blood test based Health Check to Boston Heart in the United States. The agreement includes a pilot of the potential for broader roll-out to Boston Heart’s customer base and a letter of intent regarding long-term strategic partnership.

Boston Heart is an innovative heart health focused company that provides a leading, advanced diagnostics platform to help identify and reduce the risk of cardiovascular disease, diabetes, and other chronic conditions which impose large costs upon the US healthcare system. Headquartered in Massachusetts, Boston Heart offers diagnostic testing to drive a personalized approach to improve patient health and complex chronic disease management.

The goal of the strategic partnership is to leverage Nightingale Health’s blood analysis technology in Boston Heart’s offering in the United States. The partnership will commence with a pilot and transitioning to a continued commercial service model, before making Nightingale Health’s blood test based Health Check widely available for Boston Heart’s customers. The Health Check test identifies risk across 8 common chronic diseases as well as, or better than, current risk prediction strategies. 39 biomarkers are assessed on a single small-volume blood sample. The intention of both parties is to work towards introducing Nightingale Health’s innovative solutions to the US market, with Boston Heart acting as the seller and distributor of the testing to healthcare providers.

The parties intend to start the pilot project by August 2024. The pilot has no impact on Nightingale Health’s revenue and profit. The impact of the future phases on Nightingale Health’s revenue and profit depends on the number of orders, which are not defined in the agreement.

”Preventative health has been our core mission from the start of the company. Our partnership with Boston Heart is a significant step in bringing the advantages of our technology and preventative health to the US market. Together with Boston Heart we are looking forward to reducing disease burden of chronic disease in the United States” says Teemu Suna, CEO and Founder of Nightingale Health.

For further information, please contact:

Teemu Suna, CEO
ir@nightingalehealth.com

About Boston Heart Diagnostics

Boston Heart Diagnostics ("BHD"), a subsidiary of Eurofins Scientific (EUFI.PA), is transforming the treatment of cardiovascular disease and related conditions by providing healthcare providers and their patients with novel, personalized diagnostics and integrated customized lifestyle programs that have the power to change the way clinicians and patients communicate about disease and improve health. For more information on Boston Heart Diagnostics, please visit www.bostonheartdiagnostics.com.

About Nightingale Health

Nightingale Health’s mission is to build sustainable healthcare and reduce health inequalities. Nightingale Health has developed the world’s most advanced health check that provides risk detection for multiple chronic diseases from a single blood sample. Nightingale’s Health Check can be scaled to entire populations at a low cost, and it can replace many of the current clinical risk assessments. Detecting disease risks on a population level allows for the effective targeting and tracking of health interventions, and better prevention of the onset of chronic diseases. With every sample we help to create a healthier world.

Nightingale Health operates globally with a parent company in Finland and seven subsidiaries in countries such as Japan, the United States, Singapore, and the United Kingdom. Nightingale Health has customers in more than 34 countries in the healthcare and medical research sectors. The company’s technology is being used in many of the world’s leading health initiatives, such as the UK Biobank, and over 600 peer-reviewed publications validate the technology. The company’s Series B shares are listed on the First North Growth Market Finland marketplace. Read more: https://nightingalehealth.com